The progression-free survival (PFS) was better in the ivosidenib arm: 2.7 months compared with 1.4 months in the placebo arm (HR 0.37, one-sided p < 0.0001).41 OS did not statistically differ between the two groups (HR 0.79, one-sided p = 0.093).42 In a phase II trial, 61 patients with advanced iCCA with FGFR2 alterations received infigratinib after first-line chemotherapy. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.